Comparing a strategy of sirolimus-eluting balloon treatment to drug-eluting stent implantation in de novo coronary lesions in all-comers: Design and rationale of the SELUTION DeNovo Trial.

[1]  A. Greco,et al.  Sirolimus‐coated balloon versus everolimus‐eluting stent in de novo coronary artery disease: Rationale and design of the TRANSFORM II randomized clinical trial , 2022, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  S. Mandal,et al.  Sirolimus-coated balloon with a microsphere-based technology for the treatment of de novo or restenotic coronary lesions. , 2022, Cardiovascular revascularization medicine : including molecular interventions.

[3]  P. Serruys,et al.  10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. , 2021, Journal of the American College of Cardiology.

[4]  D. Buccheri,et al.  Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease: PICCOLETO II Randomized Clinical Trial. , 2020, JACC. Cardiovascular interventions.

[5]  S. Winkler,et al.  Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial , 2020, The Lancet.

[6]  A. Perperoglou,et al.  Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: the SPARTAN DCB study , 2020, Clinical Research in Cardiology.

[7]  A. Colombo,et al.  Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry , 2020, Journal of cardiovascular medicine.

[8]  Wan Azman Wan Ahmad,et al.  Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. , 2020, JACC. Cardiovascular interventions.

[9]  I. Elgendy,et al.  Clinical and Angiographic Outcomes With Drug‐Coated Balloons for De Novo Coronary Lesions: A Meta‐Analysis of Randomized Clinical Trials , 2020, Journal of the American Heart Association.

[10]  S. Pocock,et al.  Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. , 2020, Journal of the American College of Cardiology.

[11]  R. Latini,et al.  Angiographic performance of a novel sirolimus-coated balloon in native coronary lesions: the FAtebenefratelli SIrolimus COated NATIVES prospective registry. , 2019, Journal of cardiovascular medicine.

[12]  Wan Azman Wan Ahmad,et al.  Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon. , 2019, JACC. Cardiovascular interventions.

[13]  N. Frey,et al.  Drug Coated Balloon-Only Strategy in De Novo Lesions of Large Coronary Vessels , 2019, Journal of interventional cardiology.

[14]  P. Seferovic,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[15]  J. Brachmann,et al.  Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[16]  U. Berglund,et al.  Long‐term efficacy of drug coated balloons compared with new generation drug‐eluting stents for the treatment of de novo coronary artery lesions , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[17]  N. Frey,et al.  Prospective, large‐scale multicenter trial for the use of drug‐coated balloons in coronary lesions: The DCB‐only All‐Comers Registry , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[18]  S. Winkler,et al.  Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial , 2018, The Lancet.

[19]  C. Hengstenberg,et al.  Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial. , 2017, JACC. Cardiovascular interventions.

[20]  Hiroki Shiomi,et al.  Very Late Scaffold Thrombosis of Bioresorbable Vascular Scaffold: Systematic Review and a Meta-Analysis. , 2017, JACC. Cardiovascular interventions.

[21]  O. Hlinomaz,et al.  Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study , 2016, Circulation. Cardiovascular interventions.

[22]  A. Íñiguez,et al.  A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. , 2015, Journal of the American College of Cardiology.

[23]  R. Torguson,et al.  Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[24]  J. Granada,et al.  Tissue uptake, distribution, and healing response after delivery of paclitaxel via second-generation iopromide-based balloon coating: a comparison with the first-generation technology in the iliofemoral porcine model. , 2013, JACC. Cardiovascular interventions.

[25]  F. Eberli,et al.  Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomi , 2022 .

[26]  A. Kastrati,et al.  Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial , 2013, The Lancet.

[27]  J. Brachmann,et al.  A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. , 2012, Journal of the American College of Cardiology.

[28]  Ralf Degenhardt,et al.  Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis , 2009, Circulation.

[29]  D. Desilvey.  Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. , 2007, The American journal of geriatric cardiology.

[30]  D. J. Moliterno.  Healing Achilles--sirolimus versus paclitaxel. , 2005, The New England journal of medicine.

[31]  B. Abella,et al.  Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis , 2001, Circulation.

[32]  J. Brachmann,et al.  Randomized Comparison of Bare Metal or Drug-Eluting Stent versus Drug Coated Balloon in Non-ST-Elevation Myocardial Infarction - PEPCAD NSTEMI. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.